GLP-1 & Incretin Science

The Obesity Drug That Is Not an Incretin

UKPWritten and published by UK Peptides2 min readUpdated 3 cited sources

The short answer

Setmelanotide is a melanocortin-4 receptor agonist approved for rare genetic obesity caused by defects in the MC4R pathway. It works through an entirely different mechanism from the incretins, and its VENTURE Phase 3 trial extended use to children aged 2 to 5.

Key facts

Target
Melanocortin-4 receptor (MC4R)
Not
A GLP-1 or incretin agonist
Indication
Rare MC4R pathway-associated obesity
VENTURE trial
Phase 3, ages 2-5, 1 year, open-label
Published
Lancet Diabetes Endocrinol 2025 (PMID 39549719)
Related receptor family
MC1R to MC5R

A different pathway entirely

The incretin drugs act on GLP-1, GIP and glucagon receptors. Setmelanotide acts on the melanocortin-4 receptor, part of a five-member family whose members sit in different tissues: MC1R on melanocytes driving pigmentation, MC2R in the adrenal cortex, MC3R and MC4R centrally in energy balance.

Why MC4R is a genuine obesity target

The melanocortin pathway is a central regulator of energy balance, and defects in it cause severe early-onset obesity. That is not a hypothesis. It is a defined genetic mechanism with identified patients, which is why an agonist for it could be developed for a specific indication rather than for obesity in general.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What VENTURE reported

Argente and colleagues published a one-year, open-label, multicentre Phase 3 trial of setmelanotide in patients aged 2 to 5 with rare MC4R pathway-associated obesity in the Lancet Diabetes and Endocrinology in January 2025. Extending an approved medicine into very young children with a defined genetic condition is a narrow and specific development step.

Why it is not a competitor to the incretins

Different populations entirely. Setmelanotide addresses rare monogenic obesity in identified patients; the incretins address common polygenic obesity in very large populations. They are both obesity medicines in the way that two drugs for different cancers are both oncology medicines: the category is shared and little else is.

The melanocortin connection elsewhere in this catalogue

MC4R belongs to the same receptor family this site describes in its MT-2 articles. Alpha-MSH and its derivatives act across that family, and selectivity between members is the central design problem. Setmelanotide is what a deliberately selective, regulator-assessed melanocortin agonist looks like, which is a useful contrast with compounds described as non-selective.

Regulatory position and what is not implied

Setmelanotide is a licensed medicine for a specific rare indication, prescribed and monitored clinically. Nothing supplied as research material is related to it, and no melanocortin research compound is an alternative to it or covered by its approval.

Frequently asked questions

Is setmelanotide a GLP-1 drug?

No. It targets the melanocortin-4 receptor, an entirely different mechanism from the incretins.

Who is it for?

Patients with rare genetic obesity caused by defects in the MC4R pathway, a defined and narrow population.

What did VENTURE show?

It was a one-year open-label Phase 3 trial extending setmelanotide use to children aged 2 to 5 with MC4R pathway-associated obesity.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More GLP-1 & Incretin Science articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.